logo efcs bianco


This content is also available in: English Italiano Português Deutsch Čeština Türkçe

Bookmark (0)

No account yet? Register

Arbyn M, Ronco G, Anttila A et al. (2012). Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine  30 (suppl. 5):F88-99.

Arbyn M, Roelens J, Cuscheiri K et al. (2013). The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer 132:101-8.

ASCUS-LSIL triage study group (2003a). Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 188:1393-400.

ASCUS-LSIL triage study group (2003b). Results of a randomized trial on the management of low-grade squamous intraepithelial lesion cytology intepretations. Am J Obstet Gynecol 188:1393-400.

Bowring J, Albrow R, Fisher A et al. (2013). A prospective study of human papillomavirus (HPV) testing to resolve uncertainty in colposcopy. Cytopathology 24:309-13.

Brotherton JML, Fridman M, May CL et al. (2011). Early effect of the HPV vaccination programme on cervical high-grade abnormalities in Victoria, Australia: an ecological study. Lancet 377:2085-92.

Brotherton JML, Savill AM, May CL, Chappell G, Gertig DM (2015). Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia. Cancer Causes Control 26: 953-5.

Carozzi F, Gillio-Tos A, Confortini M et al. (2013). Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INKA4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 14:168-76.

Castle PE, Schiffman M, Wheeler CM, Solomon D (2009). Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 113:18-25.

Cubie HA, Cuschieri K (2013). Understanding HPV tests and their appropriate applications. Cytopathology 24:289-308.

Evans KK, Tambouret RH, Evered A, Wilbur DC, Wolfe JM (2011). Prevalence of abnormalities influences cytologists’ error rates in screening for cervical cancer. Arch Pathol Lab Med 135:1557-60.

Flannelly G, Bolger B, Fawzi H, De Lopes AB, Monaghan JM (2001). Follow up after LLETZ: could schedules be modified according to risk of recurrence? BJOG 108:1025-30.

Innamaa A, Dudding N, Ellis K et al. (2014). High-risk HPV platforms and test of cure: should specific HPV platforms more suited to screening in a ‘test of cure’ scenario be recommended? Cytopathology DOI: 10.1111/cyt.12223 (Epub ahead of print).

Jastania R, Geddie WR, Chapman W, Boerner S (2006). Characteristics of apparently false-negative Digene Hybrid Capture 2 high-risk HPV DNA testing. Am J Clin Pathol 125:223-8.

Katki HA, Kinney WK, Fetterman B et al. (2011). Cervical cancer risk for 330,000 women undergoing concurrent HPV testing and cervical cytology in routine clinical practice at a large managed care organization. Lancet Oncol 12: 663-72.

Katki HA, Kinney WK, Fetterman B et al. (2011). Cervical cancer risk for 330,000 women undergoing concurrent HPV testing and cervical cytology in routine clinical practice at a large managed care organization. Lancet Oncol 12: 663-72.

Kelly RS, Patnick J, Kitchener HC, Moss SM on behalf of the NHSCSP HPV Special Interest Group (2011). HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer 105: 983-8.

Kitchener HC, Almonte M, Gilham C et al. (2009). ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 13;1-150.

Kitchener HC, Gilham C, Sargent A et al. (2011). A comparison of HPV DNA testing and liquid based cytology over three rounds of primary screening: extended follow up in the ARTISTIC trial. Eur J Cancer 47:864-71.

Kitchener HC (2015). HPV primary cervical screening: time for change. Cytopathology 26:4-6.

Kocken M, Helmerhorst TJ, Berkhof J et al. (2011). Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 12: 441-50.

Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A et al. (2011). Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 378:1868-73.

Mesher D, Soldan K, Howell-Jones R et al. (2013).  Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 32:26-32.

Moss SM, Kelly R, Legood R, Sadique Z et al. (2011). Evaluation of sentinel sites for HPV triage and test of cure: report to the NHS Cancer Screening Programmes. Available from www.cancerscreening.nhs.uk/cervical/sentinelfinalreport.pdf

Health and Social Care Information Centre (HSCIC) 2014. Cervical screening programme, England: statistics for 2013-14. Available from http://www.hscic.gov.uk/catalogue/PUB15968/cerv-scre-prog-eng-2013-14-rep.pdf

Qiao YL, Sellors JW, Eder PS et al. (2008). A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 9:929-36.

Rebolj M, Helmerhorst T, Habbema D et al. (2012). Risk of cervical cancer after completed post-treatment follow up of cervical intraepithelial neoplasia: population based cohort study. BMJ 345:e6855.

Rijkaart DC, Berkhof J, Rozendaal L et al. (2012) Human papillomavirus testing fot the detection of hig-grade cervical intraepithelial neoplasia: final results of the POBASCAM randomized controlled trial. Lancet Oncol 13:78-88.

Sanofi Pasteur MSD (2015). www.spmsd.co.uk/gardasil-9-hpv-vaccine-from-sanofi-pasteur-msd-granted-positive-opinion-by-european-committee-for-medicinal-products-for-human-use/

Strander B, Andersson-Ellström A, Milson I et al. (2007) Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ 335:1077 (E-pub)

World Health Organisation (2013). WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention.pdf

Zielinski GD, Bais AG, Helmerhorst TJ et al. (2004). HPV testing and monitoring of women after treatment of CIN3: review of the literature and meta-analysis. Obstet Gynecol Surv 59: 543-53.